Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $135.45 USD
Change Today +1.83 / 1.37%
Volume 467.4K
ANAC On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

anacor pharmaceuticals inc (ANAC) Snapshot

Open
$132.36
Previous Close
$133.62
Day High
$135.62
Day Low
$131.00
52 Week High
07/21/15 - $156.93
52 Week Low
09/8/14 - $21.48
Market Cap
6.0B
Average Volume 10 Days
757.9K
EPS TTM
$-1.55
Shares Outstanding
44.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANACOR PHARMACEUTICALS INC (ANAC)

anacor pharmaceuticals inc (ANAC) Related Bloomberg News

View More Bloomberg News

anacor pharmaceuticals inc (ANAC) Related Businessweek News

No Related Businessweek News Found

anacor pharmaceuticals inc (ANAC) Details

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. The company’s lead product candidate includes AN2728, anti-inflammatory product, which is in Phase III clinical trials for the treatment of mild-to-moderate atopic dermatitis and psoriasis. It is also developing AN2898, an anti-inflammatory product candidate, which has completed Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; AN3365, an antibiotic product candidate for the treatment of infections caused by Gram-negative bacteria; and AN2718, an antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin. The company has research collaborations with Drugs for Neglected Diseases initiative to develop new therapeutics for human African trypanosomiasis, visceral leishmaniasis, and Chagas disease; research and development collaboration with GlaxoSmithKline LLC for tuberculosis (TB); research, license, and commercialization agreement with Eli Lilly and Company for an animal health indication; and research agreement with The Bill & Melinda Gates Foundation for filarial worm diseases, TB, and cryptosporidiosis. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.

100 Employees
Last Reported Date: 03/16/15
Founded in 2000

anacor pharmaceuticals inc (ANAC) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $457.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $365.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $335.0K
Senior Vice President of Drug Development
Total Annual Compensation: $272.5K
General Counsel, Senior Vice President and Se...
Total Annual Compensation: $257.7K
Compensation as of Fiscal Year 2014.

anacor pharmaceuticals inc (ANAC) Key Developments

Anacor Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Expects to Submit a New Drug Application for crisaborole to the U.S. Food and Drug Administration in the First Half of 2016

Anacor Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $21,337,000 compared to $2,931,000 a year ago. Loss from operations was $11,996,000 compared to $23,425,000 a year ago. Net loss was $13,196,000 or $0.30 per basic and diluted share compared to $24,508,000 or $0.58 per basic and diluted share a year ago. Recognized $17.8 million in total KERYDIN revenue in the second quarter of 2015 under the Sandoz Agreement, representing a sequential increase of 47.5% over the first quarter of 2015. For the six months, the company reported total revenues of $36,601,000 compared to $7,089,000 a year ago. Loss from operations was $23,792,000 compared to $43,530,000 a year ago. Net loss was $26,157,000 or $0.60 per basic and diluted share compared to $45,680,000 or $1.09 per basic and diluted share a year ago. The company expects to submit a new drug application for crisaborole to the U.S. Food and Drug Administration in the first half of 2016.

Anacor Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Anacor Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Daylight on Aug 06, 2015

Anacor Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Anacor Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANAC:US $135.45 USD +1.83

ANAC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANAC.
View Industry Companies
 

Industry Analysis

ANAC

Industry Average

Valuation ANAC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 118.3x
Price/Book 91.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 114.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANACOR PHARMACEUTICALS INC, please visit www.anacor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.